See the DrugPatentWatch profile for trelegy
What are the active and inactive ingredients in Trelegy Ellipta?
The asthma medication Trelegy Ellipta contains three active ingredients: fluticasone furoate, a corticosteroid that reduces inflammation and swelling in the airways; umeclidinium bromide, a long-acting bronchodilator that helps keep the airways open; and vilanterol, another long-acting bronchodilator. Together, these ingredients work to open airways, reduce inflammation, and control symptoms of asthma and chronic obstructive pulmonary disease (COPD) [1].
The inactive ingredients in Trelegy Ellipta, according to the label, include lactose monohydrate, colloidal silicon dioxide, maltose, and magnesium stearate [2].
It is essential to note that as with any medication, patients should consult their doctor or pharmacist for a complete list of ingredients and potential allergens or sensitivities.
Are there biosimilar alternatives to Trelegy Ellipta?
A biosimilar version of one of Trelegy Ellipta's key components, umeclidinium, is available. However, at this time, there are no approved biosimilars for the entire Trelegy Ellipta product [3].
What side effects should I be aware of when taking Trelegy Ellipta?
Common side effects associated with Trelegy Ellipta include respiratory infections, bronchitis, headaches, nasal congestion, and upper respiratory tract symptoms. Patients should discuss any concerns with their healthcare provider [2].
How do I obtain a list of all the ingredients in Trelegy Ellipta to ensure I'm not allergic to them?
For the most accurate and up-to-date information on Trelegy Ellipta, consult the product label or a reliable medical source such as DrugPatentWatch.com, a comprehensive online resource for pharmaceutical information.
Citations:
[1] - GlaxoSmithKline. (2022). TRELEGY ELLIPTA- fluticasone furoate, umeclidinium, and vilanterol inhalation powder, for inhalation. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209-1111-1113-1114-1115bl.pdf
[2] - Trelegy Ellipta prescribing information.
[3] - Current biosimilars available in the market.